Neurocrine Biosciences (NASDAQ:NBIX) Announces Earnings Results

Posted by Stanley Muller on Jul 30th, 2026

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) announced its earnings results on Thursday. The company reported $2.85 EPS for the quarter, beating analysts’ consensus estimates of $1.66 by $1.19, FiscalAI reports. Neurocrine Biosciences had a net margin of 21.55% and a return on equity of 19.79%. The business had revenue of $959.00 million during the quarter, compared to analysts’ expectations of $891.16 million. During the same period in the prior year, the company earned $1.65 earnings per share. The business’s revenue was up 39.5% compared to the same quarter last year.

Here are the key takeaways from Neurocrine Biosciences’ conference call:

Strong commercial performance: Q2 revenue exceeded $950 million, up nearly 40% year over year, with non-GAAP EPS of $2.85. INGREZZA sales rose 15% to $716 million, prompting the company to raise full-year guidance to $2.825 billion–$2.875 billion.
CRENESSITY sales reached $184 million, supported by steady new-patient additions, expanding prescriber adoption, favorable reimbursement, and high persistence. Management estimates approximately 15% of diagnosed patients have been prescribed the drug, indicating substantial remaining runway.
The newly acquired VYKAT XR generated $54 million in Neurocrine-recognized Q2 sales, while pro forma sales were $94 million. Management expects sequential growth beginning in Q4 as it completes integration and works through discontinuations among patients from the initial 2025 launch bolus.
The company highlighted major anticipated 2027 catalysts, including Phase III readouts for osavampator in major depressive disorder and direclidine in schizophrenia. Neurocrine also expects to advance its obesity, muscarinic, and Friedreich’s ataxia programs.
Neurocrine ended Q2 with roughly $500 million in cash and no debt after funding the approximately $2.9 billion Soleno acquisition with cash on hand. Future earnings could face variability from acquisition-related costs, potential increased commercial investment for successful pipeline launches, and uncertainty around INGREZZA pricing under the IRA in 2029.

Neurocrine Biosciences Trading Up 2.6%

Shares of Neurocrine Biosciences stock traded up $4.71 on Thursday, reaching $185.50. 2,170,803 shares of the stock were exchanged, compared to its average volume of 1,054,397. The firm has a market capitalization of $18.65 billion, a PE ratio of 28.58, a PEG ratio of 0.76 and a beta of 0.39. Neurocrine Biosciences has a 1-year low of $122.14 and a 1-year high of $186.12. The business has a fifty day moving average price of $167.61 and a two-hundred day moving average price of $146.25.

Insider Activity

In other news, Director Leslie V. Norwalk sold 1,250 shares of the stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $182.01, for a total transaction of $227,512.50. Following the completion of the transaction, the director directly owned 1,588 shares of the company’s stock, valued at approximately $289,031.88. This represents a 44.05% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Ingrid Delaet sold 4,367 shares of the stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $181.02, for a total value of $790,514.34. Following the transaction, the insider directly owned 16,225 shares of the company’s stock, valued at approximately $2,937,049.50. This trade represents a 21.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 395,422 shares of company stock worth $62,448,693 in the last three months. 4.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Invesco Ltd. lifted its holdings in Neurocrine Biosciences by 6.1% in the fourth quarter. Invesco Ltd. now owns 343,421 shares of the company’s stock valued at $48,707,000 after acquiring an additional 19,810 shares during the period. Corient Private Wealth LLC grew its stake in shares of Neurocrine Biosciences by 82.1% during the 4th quarter. Corient Private Wealth LLC now owns 7,292 shares of the company’s stock worth $1,034,000 after purchasing an additional 3,287 shares during the period. Mercer Global Advisors Inc. ADV grew its stake in shares of Neurocrine Biosciences by 29.6% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 40,957 shares of the company’s stock worth $5,809,000 after purchasing an additional 9,355 shares during the period. EP Wealth Advisors LLC acquired a new position in shares of Neurocrine Biosciences during the 4th quarter worth $418,000. Finally, NewEdge Advisors LLC increased its holdings in shares of Neurocrine Biosciences by 5.5% in the 4th quarter. NewEdge Advisors LLC now owns 12,998 shares of the company’s stock valued at $1,844,000 after purchasing an additional 672 shares in the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on NBIX shares. Leerink Partners raised their price target on Neurocrine Biosciences from $160.00 to $170.00 and gave the stock an “outperform” rating in a report on Wednesday, April 22nd. Piper Sandler upped their price objective on Neurocrine Biosciences from $190.00 to $207.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. JPMorgan Chase & Co. increased their price objective on Neurocrine Biosciences from $177.00 to $185.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. The Goldman Sachs Group began coverage on Neurocrine Biosciences in a research note on Tuesday, June 2nd. They issued a “buy” rating and a $213.00 target price on the stock. Finally, Morgan Stanley boosted their target price on Neurocrine Biosciences from $185.00 to $191.00 and gave the company an “equal weight” rating in a report on Wednesday, May 6th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $194.05.

Get Our Latest Report on NBIX

About Neurocrine Biosciences

(Get Free Report)

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.